These reports assessed that focal PSMA-radioligands uptake could be seen both in benign and malignant thyroid nodules since both conditions are associated with the presence of neoangiogenesis [31]; however, since only one study reported a higher uptake of PSMA-radioligands in malignant lesions than in benign ones [32], more studies are needed to assess the potential of PSMA-targeted PET/CT in discriminating malignant thyroid nodules. The gene discussed is FOLH1; the disease is thyroid nodule.